Profitability Ratios
| Ratio |
Value |
| GP Margin |
69.9% |
| EBIT Margin |
-46.6% |
| EBITDA Margin |
-40.1% |
| Operating Margin |
-8.2% |
| Pretax Margin |
-47.9% |
| Cont. Ops Margin |
-44.4% |
| Net Margin |
-44.4% |
| Bottom Line Margin |
-44.4% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
2.49 |
| Quick Ratio |
2.26 |
| Solvency Ratio |
-0.922 |
| Cash Ratio |
1.12 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
-0.01 |
| Forward PEG |
-0.01 |
| Price/Book |
1.56 |
| Price/Sales |
0.70 |
| Price/FCF |
-41.58 |
| Price/Op Cash Flow |
318.77 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.2969 |
| Debt/Equity |
0.5701 |
| Debt/Capital |
0.3631 |
| Long-Term Debt/Capital |
0.3554 |
| Financial Leverage |
1.92 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
4.96 |
| Operating Cash Flow Ratio |
0.013 |
| Operating Cash Flow/Sales |
0.2% |
| Free Cash Flow/Operating Cash Flow |
-766.7% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
-17.34 |
| Interest Coverage |
-6.4571 |
| Short-Term Operating Cash Flow Coverage |
0.26 |
| Operating Cash Flow Coverage |
0.01 |
| Capital Expenditure Coverage |
0.12 |
| Dividend + Capital Expenditure Coverage |
0.12 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
8.84 |
| EPS |
-3.922 |
| Debt/Share |
2.3612 |
| Cash/Share |
1.60 |
| Book Value/Share |
3.94 |
| Tangible BV/Share |
1.75 |
| Equity/Share |
3.94 |
| Operating Cash Flow/Share |
0.019 |
| Capital Expenditure/Share |
0.167 |
| FCF/Share |
-0.148 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
0.926 |
| Earnings Before Tax/EBIT |
5.827 |
| Price/Fair Value |
1.56 |
| Debt/Market Cap |
0.3656 |
| Effective Tax Rate |
7.4% |
| Enterprise Value Multiple |
-1.92 |
MYGN - Myriad Genetics, Inc.